Serial sectioning of sentinel nodes in patients with breast cancer: A pilot study

Annals of Surgical Oncology

Volumn 5, Issue 4, 1998, Pages 310-314

  Jannink, Ilse ^a   Fan, Ming ^a   Nagy, Szaboles ^a   Rayudu, Garimella ^a   Dowlatshahi, Kambiz ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Occult metastases; Sentinel node

Indexed keywords

TECHNETIUM 99M;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER LOCALIZATION; CANCER SCINTISCANNING; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTECTOMY; PARTIAL MASTECTOMY; SURGICAL TECHNIQUE;

ADULT; AGED; AXILLA; BREAST NEOPLASMS; HISTOCYTOCHEMISTRY; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SULFUR COLLOID;

EID: 0031799808     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02303493     Document Type: Article

References (26)

1. Cady B, Stone MD, Wayne J. New therapeutic possibilities in primary invasive breast cancer. Ann Surg 1993;218:338-49.
2. Dowlatshahi K, Snider HC, Kim R. Axillary node status in non-palpable breast cancer. Ann Surg Oncol 1995;2:424-8.
3. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma. Cancer 1994;73:664-7.
4. Cady B. The need to reexamine axillary lymph node dissection in invasive breast cancer. Cancer 1994;73:505-8.
5. Saphir O, Amromin GD. Obscure axillary lymph node metastases in carcinoma of the breast. Cancer 1948;1:238-41.
6. Pickren JW. Significance of occult metastases. A study of breast cancer. Cancer 1961;14:1266-71.
7. Fisher ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978;42:2025-31.
8. International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node metastases from breast cancers. Lancet 1990;335:1565-8.
9. Krag DN, Weaver D, Alex JC, Fairbank JT. Surgical resection and radiolocalization of sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335-9.
10. Giuliano AE, Dale P, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;222:394-401.
11. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276:1818-22.
12. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-50.
13. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-node. Lancet 1997;349:1864-67.
14. Dowlatshahi K, Fan M, Rayudu GV, Krag D, Sherkeirloo M, Bloom K. Diagnostic value of axillary sentinel node in operative breast cancer-work in progress. Breast Journal 1996;2:26.
15. Fisher B, Redmond C, Fisher ER. The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology-an overview of the findings. Cancer 1980;46:1009-25.
16. Treatment alert issued for node-negative breast cancer. Monogr Natl Cancer Inst 1988;80:550-1.
17. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339(8785): 1-15.
18. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339(8785):71-85.
19. Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer in patients with estrogen receptor-negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B13 and first of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate and fluorouracil. J Clin Oncol 1996;14:1982-92.
20. Goldhirsch A, Castiglione M, Gelber RD. The International Breast Cancer Study Group. A single perioperative chemotherapy course for node-negative breast cancer: Five year results of trial v. Monogr Natl Cancer Inst 1992;11:89-96.
21. Ludwig Breast Cancer Study Group. Toxic effects of early adjuvant chemotherapy for breast cancer. Lancet 1983;2(8349):542-4.
22. Wells CA, Hcryet A, Brochier J, Gatter KC, Mason DY. The immunohistochemical detection of axillary micrometastases in breast cancer. Br J Cancer 1984;50:193-7.
23. Bussolati G, Gugliotta P, Morra I, Pietribiasi F, Berardengo E. The immunohistochemical detection of lymph node metastases from infiltrating lobular carcinoma of the breast. Br J Cancer 1986;54: 631-6.
24. Trojani M, de Mascarel I, Bonichon F, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of the breast. Br J Cancer 1987;55:303-6.
25. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
26. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-401.